Endothelin receptor antagonists

World Journal of Urology

Volumn 23, Issue 1, 2005, Pages 19-27

  Nelson, Joel B ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bone metastases; Clinical trials; Endothelin receptors; Endothelin 1; Pain; Prostate cancer

Indexed keywords

ANGIOTENSIN; ATRASENTAN; DOCETAXEL; ENDOTHELIN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; HORMONE; IBUPROFEN; INDOMETACIN; NARCOTIC AGENT; NORADRENALIN; OPIATE; RECEPTOR SUBTYPE; ZOLEDRONIC ACID;

BLOOD TOXICITY; CANCER PAIN; CLINICAL OBSERVATION; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HEADACHE; HUMAN; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MEDICAL LITERATURE; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PROSTATE CANCER; REVIEW; RHINITIS;

APOPTOSIS; CLINICAL TRIALS; DISEASE PROGRESSION; ENDOTHELIN-1; HUMANS; MALE; PROSTATIC NEOPLASMS; PYRROLIDINES; RECEPTORS, ENDOTHELIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 15844427940     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-004-0478-9     Document Type: Review

References (61)

1. Ando K, Hirata Y, Shichiri M, Emori T, Marumo F (1989) Presence of immunoreactive endothelin in human plasma. FEB Lett 245:164-166 10.1016/ 0014-5793(89)80213-3
2. Battistini B, D'Orleans-Juste P, Sirois P (1993) Biology of disease. Endothelins: Circulating plasma levels and presence in other biologic fluids. Lab Invest 68:600-628
3. Berbinschi A, Ketelslegers JM (1989) Endothelin in urine. Lancet 2:46 10.1016/S0140-6736(89)90286-9
4. Berges RR, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT (1993) Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci U S A 90:8910-8914
5. Brown KD, Littlewood CJ (1989) Endothelin stimulates DNA synthesis in Swiss 3T3 cells. Synergy with polypeptide growth factors. Biochem J 263:977-980
6. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS, Padley RJ (2002) Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics. J Clin Oncol 20:2171-2180
7. Carducci MA, Nelson JB, Humerickhouse R, Weinberg M, Schmitt J, Nabulsi A (2002) Effects of atrasentan on progression and survival in men with hormone refractory prostate cancer: Follow-up study M96-594. J Clin Oncol 21:178a
8. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB (2003) The effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone refractory prostate cancer: A randomized, placebo controlled trial. J Clin Oncol 21:679-689 10.1200/JCO.2003.04.176
9. Carducci M, Nelson JB, Saad F, Schulman CC, Dearnaley DP, Sleep DJ, Hutling M, Isaacson JD, Allan AR, Nisen P (2004) Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study. J Clin Oncol 22:384s
10. Casey ML, Word RA, MacDonald PC (1991) Endothelin-1 gene expression and regulation of endothelin mRNA and protein biosynthesis in avascular human amnion: Potential source of amniotic fluid endothelin. J Biol Chem 266:5762-5768
11. Casey ML, Byrd W, MacDonald PC (1992) Massive amounts of immunoreactive endothelin in human seminal fluid. J Clin Endocrinol Metabol 74:223-225 10.1210/jc.74.1.223
12. Cohen AJ, Belinsky S, Franklin W, Beard S (2002) Molecular and physiologic evidence for 5′ CpG island methylation of the endothelin B receptor gene in lung cancer. Chest 121:27S-28S 10.1378/chest.121.3_suppl.27S
13. Dahlof B, Gustafsson D, Hedner T, Jern S, Hansson L (1990) Regional haemodynamic effects of endothelin-1 in rat and man: Unexpected adverse reaction. J Hypertens 8:811-817
14. Daub H, Weiss FU, Wallasch C, Ullrich A (1996) Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379:557-560 10.1038/379557a0
15. Davar G, Hans G, Fareed MU, Sinnott C, Strichartz G (1998) Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport 9:2279-2283
16. De-Melo JD, Tonussi CR, D'Orleans-Juste P, Rae GA (1998) Articular nociception induced by endothelin-1, carrageenan and LPS in native and previously inflamed knee-joints in the rat: Inhibition by endothelin receptor antagonists. Pain 77:261-269 10.1016/S0304-3959(98)00098-0
17. Ferreira SH, Romitelli M, De Nucci G (1989) Endothelin-1 participation in overt and inflammatory pain. J Cardiovascular Pharmacol 13:S220-222
18. Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M (2001) Expression of endothelin receptor A associated with prostate cancer progression. J Urol 165:1033-1036 10.1097/00005392-200103000-00082
19. Gokin AP, Fareed MU, Pan HL, Hans G, Strichartz GR, Davar G (2001) Local injection of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats. J Neurosci 21:5358-5366
20. Granchi S, Brocchi S, Bonaccorsi L, Baldi E, Vinci MC, Forti G, Serio M, Maggi M (2001) Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 49:267-277 10.1002/pros.10022
21. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T (1989) The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 86:2863-2867
22. Jeronimo C, Henrique R, Campos PF, Oliveria J, Caballero OL, Lopes C, Sidransky D (2003) Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol 56:52-55 10.1136/jcp.56.1.52
23. Kimura S, Kasuya Y, Sawamura T, Shinmi O, Sugita Y, Yanigisawa M, Goto K, Masaki T (1989) Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: Structure-activity relationships of big endothelin-1. J Cardiovasc Pharmacol 13 [Suppl 5]:S5-S7
24. Kobayashi S, Tang R, Wand B et al. (1994) Localization of endothelin receptors in the human prostate. J Urol 151:763-766
25. Kusuhara M, Yamaguchi K, Nagasaki K, Hayashi C, Suzaki A, Hori S, Handa S, Nakamura Y, Abe K (1990) Production of endothelin in human cancer cell lines. Cancer Res 50:3257-3261
26. Lagenstroer P, Tang R, Shapiro E, Divish B, Opgenorth T, Lepor H (1993) Endothelin-1 in the human prostate: Tissue levels, source of production and isometric tension studies. J Urol 150:495-499
27. Lam H-C, Takahashi K, Ghatei MA, Bloom SR (1990) Presence of immunoreactive endothelin in human milk. FEBS Lett 261:184-186 10.1016/0014-5793(90)80666-7
28. Le Brun G, Aubin P, Soliman H, Ropiquet F, Villette J-M, Berthon P, Creminon C, Cussenot O, Fiet J (1999) Upregulation of endothelin 1 and its precursor by IL-1β, TNF-α, and TGF-β in the PC3 human prostate cancer cell line. Cytokine 11:157-162 10.1006/ cyto.1998.0407
29. Lo K-W, Tsang Y-S, Kwong J, To K-F, Teo PML, Huang DP (2002) Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma. Int J Cancer 95:651-655 10.1002/ijc.10271
30. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1:944-949
31. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW (1996) Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56:663-668
32. Nelson JB, Lee W-H, Nguyen SH, Jarrard DF, Brooks JD, Magnuson SR, Opgenorth TJ, Nelson WG, Bova GS (1997) Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 57:35-37
33. Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LWK, Inoue N (1999) New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53:1063-1069 10.1016/S0090-4295(98)00658-X
34. Nelson JB, Opgenorth TJ, Fleisher LA, Frank SM (1999) Perioperative plasma endothelin-1 and big endothelin-1 concentrations in elderly patients undergoing major surgical procedures. Anesth Analg 88:898-903 10.1097/00000539-199904000-00039
35. Nelson JB, Carducci MA (1999) The role of the endothelin axis in prostate cancer. Prostate J 1:126-130 10.1046/j.1525-1411.1999.09922.x
36. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA (2003) Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan J Urol 169:1143-1149 10.1097/01.ju.0000042162.08938.27
37. Nelson JB, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3:110-116
38. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, Gehrke LJ, Hernandez L, Magnuson SR, Marsh KC, Novosad EI, Von Geldern TW, Wessale JL, Winn M, Wu-Wong JR (1996) Pharmacological characterization of A-127722: An orally active and highly potent ET-selective receptor antagonist. JPET 276 473-481
39. Pao MM, Tsutsumi M, Liang G, Uzvolgy E, Gonzales FA, Jones PA (2001) The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet 10:903-910 10.1093/hmg/10.9.903
40. Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C. Scher HI, Albino AP, Nanus DM (1998) Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 4:50-57
41. Peters CM, Lindsay TH, Pomonis JD, Luger NM, Ghilardi JR, Sevcik MA, Mantyh PW (2004) Endothelin and the tumorigenic component of bone cancer pain. Neuroscience 126:1043-1052
42. Pflug B.R. Nelson J.B. Udan M.S. 2001 Endothelin-B receptor mediates apoptosis in prostate cancer cells J Urol 165:50
43. Piovezan AP, D'Orleans-Juste P, Souze GE, Rae GA (2000) Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: Modulation by simultaneous ET(B) receptor activation. Br J Pharmacol 129:961-968
44. Prayer-Galetti T, Rossi GP, Belloni AS, Albertin G, Battanello W, Piovan V, Gardiman M, Pagano F (1997) Gene expression and autoradiographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate. J Urol 157 2334-2339 10.1097/ 00005392-199706000-00109
45. Raffa RB, Schupsky JJ, Martinez RP, Jacoby HI (1991) Endothelin-1 induced nociception Life Sci 45:PL61-65 10.1016/0024-3205(91)90252-7
46. Raffa RB, Schupsky JJ, Lee DK, Jacoby HI (1996) Characterization of endothelin-induced nociception in mice: Evidence for a mechanistically distinct analgesic model. J Pharmacol Exp Ther 278:1-7
47. Saita Y, Yazawa H, Koizumi T, Morita T, Tamura T, Takenaka T, Honda K (1998) Mitogenic activity of endothelin on human cultured prostatic smooth muscle cells. Eur J Pharmacol 349:123-128 10.1016/ S0014-2999(98)00183-6
48. Samara E, Dutta S, Cao G, Granneman GR, Dordal MS, Padley RJ (2001) Single-dose pharmacokinetics of atrasentan, and endothelin-A receptor antagonist. J Clin Pharmacol 41:397-403 10.1177/00912700122010258
49. Schichiri M, Hirata Y, Nakajima T, Ando K, Imai T, Yanagisawa M, Masaki T, Marumo F (1991) Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J Clin Invest 87:1867-1871
50. Suzuki N, Matsumoto H, Kitada C, Kimura S, Fujino M (1989) Production of endothelin-1 and big-endothelin-1 by tumor cells with epithelial-like morphology. J Biochem 106:736-741
51. ++ from extra- and intracellular pools in osteoblastic cells Am J Physiol 257 E797-E803
52. Udan MS, Pflug BR, Nelson JB (2000) Endothelin-1 promotes survival of prostate cancer cells through activation of AKT. J Urol 163:31
53. Verhaar MC, Grahn AY, Van Weerdt AWM, Honing MLH, Morrison PJ, Yang YP, Padley RJ, Rabelink TJ (2000) Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans. Br J Clin Pharmacol 49:562-573 10.1046/j.1365-2125.2000.00171.x
54. Wacnik PW, Eikmeier LJ, Ruggles TR, Ramnaraine ML, Walcheck BK, Beitz AJ, Wilcox GL (2001) Functional interactions between tumor and peripheral nerve: Morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci 21:9355-9366
55. Woodson K, Hanson J, Tangrea J (2004) A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett 205:181-188 10.1016/j.canlet.2003.11.027
56. Yamaji T, Johshita H, Ishibashi M, Takaku F, Ohno H, Suzuki N, Matsumoto H, Fujino M (1990) Endothelin family in human plasma and cerebrospinal fluid. J Clin Endocrinol Metab 71:1611-1615
57. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415 10.1038/ 332411a0
58. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64:1975-1986
59. Yin JJ, Mohammad KS, KaKonen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett R, Chirgwin JM, Guise TA (2003) A causal role of endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 100:10954-10959 10.1073/pnas.1830978100
60. Zhou Z, Davar G, Strichartz G (2002) Endothelin-1 (ET-1) selectively enhances the activation gating of slowly inactivating tetrodotoxin-resistant sodium currents in rat sensory neurons: A mechanism for pain-inducing actions of ET-1. J Neurosci 22 6325-6330
61. Zonnenberg BA, Groenewegen G, Janus T.J, Leahy TW, Humerickhouse RA, Isaacson JD, Carr RA, Voest E (2003) Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: An endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 9 2965-2972